Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-2: Orforglipron versus placebo in adults with type 2 diabetes mellitus and overweight or obesity
CTR20232573Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of orforglipron in type 2 diabetes mellitus (T2DM), obesity and Overweight (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Mean percent change from baseline in body weight. Started Oct 2023; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on CTR20232573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232573.